Benchmark analyst Robert Wasserman downgraded Emergent BioSolutions to Hold from Buy with no price target after Emergent reported in-line financial results for fiscal Q2. Emergent recently announced plans to strengthen its core medical countermeasure business, including Narcan, reduce costs, and improve operational efficiencies, notes the analyst, who is lowering the firm’s rating until the company can complete its business line restructuring.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
- Biotech Alert: Searches spiking for these stocks today
- Advance Auto Parts to replace Emergent BioSolutions in S&P 600 at open on 8/25
- Emergent BioSolutions sees 2023 revenue $1.0B-$1.1B vs. prior $1.1B-$1.2B
- Emergent BioSolutions sees Q3 revenue $210M-$250M, consensus $326.87M